EQL Pharma AB (7JK) Stock Statistics & Valuation Metrics

EQL Pharma AB has a market cap or net worth of €63.57M. The enterprise value is €2.32B.

EQL Pharma AB has 29,529,610 shares outstanding. The number of shares has decreased by -2.65% in one year.

EQL Pharma AB’s return on equity (ROE) is ― and return on invested capital (ROIC) is ―.

The current PE Ratio of EQL Pharma AB is 53.5. EQL Pharma AB’s PEG ratio is ―.

In the last 12 months, EQL Pharma AB had revenue of ― and earned 31.55M in profits. Earnings per share was ―.

In the last 12 months, operating cash flow was ― and capital expenditures ―, giving a free cash flow of ― billion.

EQL Pharma AB pays an annual dividend of ―, resulting in a dividend yield of ―

EQL Pharma AB upcoming earnings date is Aug 18, 2026, TBA (Not Confirmed).

EQL Pharma AB as a current ratio of ―, with Debt / Equity ratio of ―

In the past 12 months, EQL Pharma AB has paid ― in taxes.

EQL Pharma AB EV to EBITDA ratio is ―, with an EV/FCF ratio of ―.

EQL Pharma AB has ― in cash and marketable securities with ― in debt, giving a net cash position of ― billion.

Gross margin is ―, with operating margin of ―, and net profit margin of ―.

The average price target for EQL Pharma AB is ―, which is 11.43% higher than the current price. The consensus rating is ―